Case Details
- Citation: [2007] SGHC 51
- Court: High Court of the Republic of Singapore
- Date: 2007-04-12
- Judges: Tan Lee Meng J
- Plaintiff/Applicant: Dextra Asia Co Ltd and Another
- Defendant/Respondent: Mariwu Industrial Co (S) Pte Ltd
- Legal Areas: Patents and Inventions — Novelty
- Statutes Referenced: Evidence Act
- Cases Cited: [2007] SGHC 51
- Judgment Length: 7 pages, 3,740 words
Summary
This case involves a dispute over the alleged infringement of a patent for a manufacturing process owned by Dextra Asia Co Ltd and Dextra Manufacturing Co Ltd (collectively "Dextra"). The defendant, Mariwu Industrial Co (S) Pte Ltd ("Mariwu"), claimed that the patent was not novel because the process had been used in France and Hong Kong prior to the patent's priority date. The High Court of Singapore initially found in favor of Dextra, but the case was remitted to the trial judge to consider additional evidence regarding the patent's novelty.
What Were the Facts of This Case?
In 2006, the High Court of Singapore held that Dextra, the owners of rights in Asia to the "Bartec" patented invention used in reinforcing concrete, were entitled to damages from Mariwu for infringing the patent. Mariwu appealed the decision, arguing that the patent was not novel because the Bartec process had been used in France and Hong Kong before the priority date.
Before the appeal was heard, Mariwu successfully applied to the Court of Appeal to admit additional evidence related to events in 1994. At that time, Dextra was a licensee of the Bartec patent, paying royalties to the patent owner, Etablissements A Mure ("Mure"). Dextra collaborated with another Bartec licensee, CCL Systems Limited ("CCL"), to pressure Mure not to sell the patent to a common competitor and to reduce the royalty rate.
The additional evidence included correspondence between Dextra, CCL, and Mure in late 1994, as well as an internal CCL memorandum about a meeting in Lyon, France on November 3, 1994 attended by representatives of the three companies. The Court of Appeal remitted the case to the trial judge to hear this further evidence.
What Were the Key Legal Issues?
The key legal issue in this case was whether the Bartec patent was valid and novel, or whether it had been invalidated by prior use of the patented process in France and Hong Kong before the priority date. Mariwu argued that the additional evidence showed that Dextra and its collaborator CCL had asserted the patent was invalid due to prior use, and that Mure had admitted as much at the Lyon meeting.
The court also had to determine the credibility of the witnesses, particularly Dr. Pithon of Dextra and Mr. Copping of CCL, and whether their statements about the patent's validity were truthful or merely bargaining tactics to pressure Mure.
How Did the Court Analyse the Issues?
The court closely examined the additional evidence, including the correspondence between the parties and the summary of the Lyon meeting. It found that Dr. Pithon and Mr. Copping had both asserted the patent was invalid due to prior use, but they admitted this was a "bluff" or "gamesmanship" to pressure Mure into reducing the royalty rates.
The court noted that if Dextra had truly believed the patent was invalid, it likely would not have continued paying the 5% royalty to Mure. The court also found that the summary of the Lyon meeting was not corroborated by Mr. Copping's testimony, and that Mure did not actually admit the patent was invalid at that meeting.
Ultimately, the court concluded that Dextra and CCL were using the alleged invalidity of the patent as a bargaining tool, but that Dr. Pithon and Mr. Copping did not have any real evidence to support their claims of prior use invalidating the patent.
What Was the Outcome?
The High Court of Singapore ruled in favor of Dextra, finding that the additional evidence did not establish that the Bartec patent was invalid due to prior use in France or Hong Kong. The court held that Dextra and CCL's assertions of invalidity were merely bargaining tactics, not supported by actual evidence.
As a result, the court's original finding that Dextra was entitled to damages from Mariwu for infringing the valid Bartec patent was upheld.
Why Does This Case Matter?
This case provides important guidance on the burden of proof for challenging the novelty of a patent. The court made clear that mere assertions of prior use, even if made by the patent owner, are not sufficient to invalidate a patent. The party challenging novelty must present actual evidence that the patented invention was publicly used or disclosed before the priority date.
The case also highlights the risks of using unsubstantiated claims about a patent's validity as a negotiating tactic. The court was critical of Dextra and CCL's "bluffing" strategy, finding it undermined their credibility. This serves as a warning to patent owners and licensees to be cautious about making unsupported statements that could later be used against them.
Overall, Dextra Asia Co Ltd v Mariwu Industrial Co (S) Pte Ltd reinforces the high bar for proving a lack of novelty in patent infringement cases, and the importance of substantiating any challenges to a patent's validity.
Legislation Referenced
- Evidence Act
Cases Cited
- [2007] SGHC 51
- [2006] 2 SLR 154
Source Documents
This article analyses [2007] SGHC 51 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.